Search
forLearn
5 / 801 resultslearn Gluco peptide
learn multipeptides
learn glutamic acid
learn oligopeptide-71
Research
5 / 235 resultsresearch Frontal fibrosing alopecia shows robust T helper 1 and Janus kinase 3 skewing
Frontal fibrosing alopecia is linked to increased immune system activity and reduced stem cells, suggesting early treatment targeting this pathway might prevent hair follicle damage.
research 917 Frontal fibrosing alopecia scalp profiling links Th1/Th2 and JAK3 activation with fibrosis and loss of follicular stem cells
Targeting immune pathways like JAK/STAT may help treat frontal fibrosing alopecia.
research Granzyme B in Autoimmune Skin Disease
Granzyme B is important in autoimmune skin diseases and could be a new treatment target.
research Type 1 interferon signature in the scalp lesions of alopecia areata
Alopecia areata shows a unique type 1 interferon signature, suggesting potential treatment by targeting this pathway.
research Role of Cytotoxic T Cells in Chronic Alopecia Areata
Cytotoxic T cells cause hair loss in chronic alopecia areata.
Community Join
5 / 1000+ resultscommunity Breezula phase 3 results said to be released next month
Breezula's phase 3 results are expected soon, with discussions on the effectiveness of androgen receptor antagonists like spironolactone and the potential of GT20029. Users express skepticism about new treatments and discuss the complexities of male pattern baldness, often relying on finasteride despite its side effects.
community Cassiopea announces completion of recruitment of Phase II dose ranging trial of Breezula (CB-03-01) for androgenic alopecia
The conversation discusses the completion of a Phase II trial recruitment for Breezula (CB-03-01), a potential treatment for androgenic alopecia. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.
community AH-001 another topical AR degrader beside GT20029, completed Phase I
AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.
community When will Breezula be released and how does it compare to KX-826?
Breezula (clascoterone) is expected to be available by late 2026, showing good long-term results with minimal side effects. KX-826 (pyrilutamide) acts faster but is still in earlier development stages.
community Anagenic is trying to compound Gt20029
The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.